Nurix Q1 2024 Earnings Report
Key Takeaways
Nurix Therapeutics reported revenue of $16.6 million for the first quarter of fiscal year 2024, compared to $12.7 million for the same period in the previous year. The net loss for the quarter was $41.5 million, or $0.76 per share, compared to a net loss of $40.7 million, or $0.75 per share, for the first quarter of fiscal year 2023.
Extended the strategic collaboration with Gilead Sciences.
Extended the strategic collaboration with Sanofi to develop novel orally available targeted protein degrader of STAT6.
Presented new case studies on NX-5948 demonstrating clinical responses in patients with CNS lymphoma and CLL with CNS involvement.
Announced that Nurix is part of a team of experts selected as awardees in this year’s Cancer Grand Challenges.
Nurix
Nurix
Nurix Revenue by Segment
Forward Guidance
Nurix expects to continue to achieve substantial research collaboration milestones throughout the terms of its collaborations with Gilead, Sanofi and Pfizer.